# Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

> **NCT06290765** · PHASE4 · NOT_YET_RECRUITING · sponsor: **PharmaEssentia** · enrollment: 70 (estimated)

## Conditions studied

- Polycythemia Vera
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Ropeginterferon alfa-2b
- **PROCEDURE:** Phlebotomy and aspirin

## Key facts

- **NCT ID:** NCT06290765
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06290765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06290765, "Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06290765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*